# Latigo Stock May Profit From Vertex Market

> Latigo Biotherapeutics (LTGO) could see significant gains as Vertex's market groundwork supports its onzotrigine trials.
- Title: Latigo Stock May Profit From Vertex Market · Seekingalpha
- Summary: Latigo Biotherapeutics (LTGO) could see significant gains as Vertex's market groundwork supports its onzotrigine trials. Latigo Biotherapeutics stock may…
- Keywords: latigo, vertex, nav1.8, onzotrigine, journavx, phase 2, phase 3, bunionectomy, stock, nasdaq, ltgo, investor
- Source: Seekingalpha — https://seekingalpha.com/article/4953368-vertex-built-the-nav1-8-market-latigo-may-be-the-one-to-profit-from-it
- Author: Equity Eagle
- Published: 2026-10-11T20:31:21+00:00
- Read time: 1 min
- Topics: latigo, vertex, nav1.8, onzotrigine, journavx, phase 2, phase 3, bunionectomy, stock, nasdaq, ltgo, investor
## Latigo Stock Undervalued
Latigo Biotherapeutics is undervalued below IPO with onzotrigine showing superior efficacy to Vertex's Journavx in acute pain.
## Vertex Market Groundwork
LTGO leverages Vertex's market groundwork, has pivotal-eligible Phase 2 data, and is funded into 2029 reducing near-term financing risk.
## Key Trial Event
Onzotrigine's Phase 3 bunionectomy trial is the key binary event; positive results could drive significant upside versus current market expectations.
## Key takeaway

Latigo Biotherapeutics stock may rise due to Vertex's market groundwork and onzotrigine's Phase 3 trial results.